Trial Profile
A Study of Conversion Therapy Using Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Systemic Oxaliplatin/S1 Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Mar 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur; Lobaplatin; Oxaliplatin
- Indications Cancer metastases; Gastric cancer
- Focus Therapeutic Use
- 22 Mar 2020 Status changed from recruiting to discontinued.
- 08 Mar 2020 Planned primary completion date changed from 30 Nov 2018 to 30 Nov 2020.
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.